Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | GAA | P10253 | 2/20 | 0.40 |
| ▸ | POLB | P06746 | 2/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | RORC | P51449 | 2/20 | 0.37 |
| ▸ | NAMPT | P43490 | 1/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.37 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.36 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.36 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.36 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | DPP4 | P27487 | 1/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20307140 | 0.89 | LMNA (0.45) | LMNASMN1; SMN2GAAPOLBKDM4E | |
| SCHEMBL18309361 | 0.87 | LMNA (0.50) | LMNASMN1; SMN2GAAPOLBKDM4E | |
| SCHEMBL18309358 | 0.80 | LMNA (0.44) | LMNASMN1; SMN2GAAPOLBKDM4E | |
| SCHEMBL26882752 | 0.80 | LMNA (0.46) | LMNASMN1; SMN2GAAPOLBKDM4E | |
| SCHEMBL21540636 | 0.79 | LMNA (0.50) | LMNASMN1; SMN2GAAPOLBKDM4E | |
| SCHEMBL17034780 | 0.79 | LMNA (0.42) | LMNASMN1; SMN2GAAPOLBKDM4E | |
| SCHEMBL17037049 | 0.78 | POLB (0.62) | SMN1; SMN2POLBNAMPTCYP1A2CYP2C9 | |
| SCHEMBL20307128 | 0.77 | KMT2A (0.35) | LMNASMN1; SMN2GAACYP1A2CYP2C9 | |
| SCHEMBL2757925 | 0.77 | LMNA (0.60) | LMNASMN1; SMN2GAAPOLBKDM4E | |
| SCHEMBL28186001 | 0.77 | LMNA (0.60) | LMNASMN1; SMN2GAAPOLBKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10005802-B2 | Amide compounds for treatment of complement mediated disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2018-06-26 | — | — | US | disclosed |
| US-10005802-B2 | Amide compounds for treatment of complement mediated disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2018-06-26 | — | — | US | disclosed |
| US-20170298084-A1 | AMIDE COMPOUNDS FOR TREATMENT OF COMPLEMENT MEDIATED DISORDERS | ACHILLION PHARMACEUTICALS, INC. (US) | 2017-10-19 | — | — | US | disclosed |
| US-9695205-B2 | Amide compounds for treatment of complement mediated disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2017-07-04 | — | — | US | disclosed |
| US-20160362398-A1 | AMIDE COMPOUNDS FOR TREATMENT OF COMPLEMENT MEDIATED DISORDERS | ACHILLION PHARMACEUTICALS, INC. (US) | 2016-12-15 | — | — | US | disclosed |
| US-20150239893-A1 | Amide Compounds for Treatment of Complement Mediated Disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2015-08-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160362398-A1 | AMIDE COMPOUNDS FOR TREATMENT OF COMPLEMENT MEDIATED DISORDERS | CFD, TFPI, CFH | LMNA 2178/4885SMN1; SMN2 2038/4885GAA 3877/4885 |
| US-20170298084-A1 | AMIDE COMPOUNDS FOR TREATMENT OF COMPLEMENT MEDIATED DISORDERS | CFD, TFPI, C9 | LMNA 2004/4885SMN1; SMN2 1358/4885GAA 4379/4885 |
| US-10005802-B2 | Amide compounds for treatment of complement mediated disorders | CFD, TFPI, CFH | LMNA 2178/4885SMN1; SMN2 2038/4885GAA 3877/4885 |
| US-20150239893-A1 | Amide Compounds for Treatment of Complement Mediated Disorders | CFD, TFPI, C9 | LMNA 2004/4885SMN1; SMN2 1358/4885GAA 4379/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.